Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mariska Klepper is active.

Publication


Featured researches published by Mariska Klepper.


Transplantation | 2005

Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells.

Carla C. Baan; Barbara J. van der Mast; Mariska Klepper; Wendy M. Mol; A.M.A. Peeters; Sander S. Korevaar; A. H. M. M. Balk; Willem Weimar

Background. The transcription factor FOXP3 has been identified as the molecule associated with the regulatory function of CD25+ T cells. Methods. To understand the biology of FOXP3+ T cells in allogeneic reactions, we measured FOXP3 mRNA expression levels in allostimulated CD25 bright+ cells and CD25 intermediate( int)/- cells and in peripheral blood mononuclear cells (PBMC). The effect of immunosuppressive drugs on FOXP3 expression was studied in mixed lymphocyte reactions (MLR) in the presence and absence of calcineurin inhibitors (CNI), &agr;CD25 mAb, and Rapamycin (Rapa), and analyzed in biopsies from cardiac allograft recipients during acute rejection by quantitative (Q)-PCR. Results. FOXP3 mRNA expression was restricted to the CD25 bright+ population that inhibited the proliferation of allostimulated CD25 int/- cells. In the MLR FOXP3 was readily induced after allostimulation. Kinetic examination of the MLR showed a 10–20-fold higher FOXP3 mRNA expression level after 5 days of culture. The CNI Cyclosporin and Tacrolimus, and &agr;CD25 mAb inhibited in vitro induced FOXP3 gene transcription (range 70%–90%), whereas Rapa did not inhibit the induction. After clinical heart transplantation the highest FOXP3 mRNA expression levels were measured in biopsies during acute rejection (P=0.03). Conclusions. The high FOXP3 mRNA levels during allogeneic responses in vivo and in vitro suggests that regulatory activities of CD25 bright+ T cells or the generation of these cells is an intrinsic part of activation. CNI and &agr;CD25 mAb in contrast to Rapa, did interfere with this immunosuppressive counter-mechanism and as a result might have an inhibitory effect to tolerance induction after transplantation.


Transplant International | 2009

Monotherapy rapamycin allows an increase of CD4+ CD25bright+ FoxP3+ T cells in renal recipients

Thijs K. Hendrikx; Jurjen H.L. Velthuis; Mariska Klepper; Eveline A. F. J. van Gurp; Annemarie Geel; Wenda Schoordijk; Carla C. Baan; Willem Weimar

CD4+ CD25bright+ FoxP3+ regulatory T cells (Tregs) may control donor‐specific allogeneic responses in kidney transplant recipients. Recent evidence demonstrated that three phenotypical Treg‐subsets, naive (CCR7+CD45RO−), central‐memory (CCR7+CD45RO+) and effector‐memory (CCR7−CD45RO+), are essential for the development and function of antigen‐specific suppression in the lymphoid and peripheral tissues. Also, it has been appreciated that Tregs are affected by immunosuppressive agents. In clinical practice, however, the effect of a single drug remains to be determined. Therefore, we analyzed the effect of several immunosuppressive agents on the number, phenotype and function of peripheral Tregs from 46 stable kidney transplant recipients. These patients were converted to monotherapy with tacrolimus (n = 15), rapamycin (n = 17) or mycophenolate mofetil (n = 14). Blood was obtained at inclusion and 6 months thereafter. The number of Tregs increased significantly in patients on monotherapy with rapamycin (P < 0.001), which was caused by increased numbers of Tregs with a central‐memory and an effector‐memory phenotype (both P < 0.05). At 6 months after conversion, however, the suppressive function of Tregs did not significantly change in co‐cultures stimulated with donor‐Ag. Therefore, monotherapy with rapamycin allows the signals that are needed to increase the number of functional Tregs with a memory phenotype, thereby enhancing the potential capacity to regulate donor‐specific responses in the lymphoid and the peripheral tissues.


Transplantation | 2009

The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.

Evelien A. F. J. van Gurp; Wenda Schoordijk-Verschoor; Mariska Klepper; Sander S. Korevaar; G. Chan; Willem Weimar; Carla C. Baan

Introduction. CP-690,550 inhibits Janus kinase 3 (JAK3) which mediates signal transduction of receptors of the common γ-chain cytokines. These cytokines play key roles in lymphocyte function and homeostasis. As part of a phase 1 trial, we evaluated the effect of CP-690,550 on immune parameters. Material. Stable kidney transplant recipients (n=8) receiving mycophenolate mofetil and prednisolone were treated with CP-690,550, 30 mg twice daily orally for 29 days. Blood samples were collected on days 1 (before first dose), 15, 29 (end of treatment), and 57. Results. Two patients experienced minor infections (one urinary tract infection and one mild respiratory tract infection). Leukocyte counts remained stable, whereas a mean decrease in hemoglobulin of 8% was measured (P=0.01). CP-690,550 treatment for 29 days resulted in statistically significant changes in the number of circulating CD19+ B cells (P=0.05), CD3−CD16+CD56+ natural killer-cells (P<0.01), and CD4+CD25bright+ T cells (P=0.05; one-way analysis of variance). After CP-690,550 treatment on day 15 the number of B cells increased by a mean of 100%, (P=0.04), whereas those of natural killer cells and CD4+CD25bright+ T cells decreased by 65% (P=0.001) and 38% (P=0.03, t test), respectively, from pretreatment baseline. However, the regulatory capacities of the residual CD4+CD25bright+ T cells remained unchanged pre- and posttreatment. In addition, in the presence of CP-690,550, the interferon-γ production capacity of peripheral blood mononuclear cells was reduced by 39% (median) compared with predose baseline (P=0.01). Conclusions. These findings demonstrate the role of JAK3 in the homeostasis and function of select lymphocyte subpopulations. JAK3 inhibition may provide a novel mechanism for the modulation of allogeneic responses in patients after transplantation.


Nephrology Dialysis Transplantation | 2014

The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients

Anne P. Bouvy; Mariska Klepper; Marcia M.L. Kho; Karin Boer; Michiel G.H. Betjes; Willem Weimar; Carla C. Baan

BACKGROUND To evaluate the influence of induction therapy on Tregs we investigated their origin, kinetics and function in kidney transplant patients after treatment with T-cell depleting rabbit antithymocyte globulin (rATG) or IL-2 receptor antagonist basiliximab. METHODS Flow cytometry was used to study thymopoiesis by CD31+ naïve Tregs, homeostatic proliferation by Ki-67+ Tregs and Treg origin by the expression of Helios (nTreg-marker). FACSsorted Tregs were analysed for the demethylation status of the Treg-specific demethylated region (TSDR) of the FoxP3 gene, and Treg-suppressive function. RESULTS Differential effects of rATG and basiliximab induction therapies were measured on the repopulation kinetics of Tregs. While decreased absolute numbers of Tregs were found in both study arms, increased percentages of Tregs were found in rATG treated patients and decreased percentages in basiliximab treated patients. In both groups, Treg repopulation was the result of homeostatic proliferation and not of thymopoiesis. At 1 month after rATG and 6 months after basiliximab therapy, high percentages of Ki-67+ Treg were measured, which in the rATG group, was accompanied by low percentages of Ki-67+Helios+ Treg, and by cells with a demethylated TSDR in the FoxP3 gene. After both rATG and basiliximab therapy, repopulated Tregs inhibited proliferation of allo-antigen activated T effector cells (Teff). CONCLUSIONS In kidney transplant patients, repopulation of Treg after rATG and basiliximab therapy is the result of homeostatic proliferation and not of thymopoiesis. These repopulated Treg were functional after both induction strategies; however only after rATG therapy, were increased proportions of Helios(-) methylated FoxP3 Treg found.


Transplantation | 2007

Interleukin-21: An interleukin-2 dependent player in rejection processes

Carla C. Baan; A. H. M. M. Balk; Esme Dijke; Sander S. Korevaar; Anna Peeters; Ronella de Kuiper; Mariska Klepper; Pieter E. Zondervan; Alex P.W.M. Maat; Willem Weimar

Background. Interleukin (IL)-21 is the most recently described cytokine that signals via the common cytokine receptor (γc), is produced by activated CD4+ T-cells, and regulates expansion and effector function of CD8+ T-cells. Materials. To explore the actions of IL-21 with other γc-dependent cytokines in alloreactivity, mRNA expression of IL-21, IL-21R α-chain, and IL-2 proliferation and cytotoxicity was measured after stimulation in mixed lymphocyte reactions. Additionally, IL-21 and IL-21R α-chain expression was studied in biopsies of heart transplant patients. Results. Analysis of mRNA expression levels of allostimulated T-cells showed a 10-fold induction of IL-21 and IL-21R α-chain. Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R α-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated. IL-21 functioned as a costimulator for IL-2 to augment proliferation and cytotoxic responses, while blockade of the IL-2 route abrogated these functions of IL-21. Blockade of the IL-21 route by anti-IL-21R α-chain monoclonal antibodies inhibited the proliferation of alloactivated T-cells. Also, in vivo alloreactivity was associated with IL-21/IL-21R α-chain expression. After heart transplantation, the highest intragraft IL-21, IL-21R α-chain, and IL-2 mRNA expression levels were measured during acute rejection (P<0.001, P=0.01, P=0.03). Conclusion. IL-21 is a critical cytokine for IL-2 dependent immune processes. Blockade of the IL-21 pathway may provide a new perspective for the treatment of allogeneic responses in patients after transplantation.


Clinical Transplantation | 2007

Functional CD25bright+ alloresponsive T cells in fully immunosuppressed renal allograft recipients

Carla C. Baan; Jurjen H.L. Velthuis; Evelien A. F. J. van Gurp; Wendy M. Mol; Mariska Klepper; Jan N. M. IJzermans; Willem Weimar

Abstract:  Background:  Evidence from animal studies indicate a crucial role for CD25bright+ regulatory T cells in transplantation tolerance.


Clinical Transplantation | 2008

Functional analysis of CD4+ CD25bright T cells in kidney transplant patients : improving suppression of donor-directed responses after transplantation

Varsha D. K. D. Sewgobind; Luc J. W. van der Laan; Mariska Klepper; Jan N. M. IJzermans; H.W. Tilanus; Willem Weimar; Carla C. Baan

Abstract:  Background:  The role of CD4+ CD25bright regulatory T cells (Treg) in controlling alloreactivity is established, but little is known whether antigen‐specific Treg are induced in fully immunosuppressed kidney transplant patients.


Transplantation | 2013

Kinetics of homeostatic proliferation and thymopoiesis after rATG induction therapy in kidney transplant patients.

Anne P. Bouvy; Marcia M.L. Kho; Mariska Klepper; Nicolle H.R. Litjens; Michiel G.H. Betjes; Willem Weimar; Carla C. Baan

Background Lymphocyte-depleting therapy is associated with long-lasting effects on repopulated T cells and subsequent increased rates of infections and malignancies. The mechanisms of T-cell repopulation and their posttransplantation kinetics are not fully understood. Methods We studied thymopoiesis by CD31+ naïve T cells (recent thymic emigrants) and homeostatic proliferation by Ki-67+ T cells in rabbit antithymocyte globulin (rATG)–treated patients the first 6 months after transplantation. Patients receiving basiliximab or no induction therapy served as controls. Results At 6 months after transplantation, T-cell numbers were lower than before transplantation in rATG-treated patients, whereas T-cell numbers remained stable in both control groups. In this time period, thymopoiesis was similar between the three treatment groups; CD8+ T cells showed the highest percentage of recent thymic emigrants. At month 1, percentages of Ki-67+ naïve and memory CD4+ and CD8+ T cells were the highest in rATG-treated patients, but these percentages declined in the months thereafter. When CD31 was used to distinguish between cytokine- and antigen-driven proliferation in naïve T cells, we found evidence for cytokine-dependent proliferation. Cytokine-dependent proliferation was also shown by in vivo increased percentages of phosphorylated STAT5 and high expression levels of the interleukin-7 receptor-&agr; and interleukin-15 receptor-&agr; by T cells. Conclusion These findings demonstrate that, in the first month after rATG therapy, cytokine-induced homeostatic proliferation is involved in T-cell repopulation of both naïve and memory T cells. At later time points, the contribution of homeostatic proliferation diminished, which explains the observed incomplete T-cell recovery.


PLOS ONE | 2016

Loss of CD28 on Peripheral T Cells Decreases the Risk for Early Acute Rejection after Kidney Transplantation

Burç Dedeoglu; Ruud W. J. Meijers; Mariska Klepper; Dennis A. Hesselink; Carla C. Baan; Nicolle H.R. Litjens; Michiel G.H. Betjes

Background End-stage renal disease patients have a dysfunctional, prematurely aged peripheral T-cell system. Here we hypothesized that the degree of premature T-cell ageing before kidney transplantation predicts the risk for early acute allograft rejection (EAR). Methods 222 living donor kidney transplant recipients were prospectively analyzed. EAR was defined as biopsy proven acute allograft rejection within 3 months after kidney transplantation. The differentiation status of circulating T cells, the relative telomere length and the number of CD31+ naive T cells were determined as T-cell ageing parameters. Results Of the 222 patients analyzed, 30 (14%) developed an EAR. The donor age and the historical panel reactive antibody score were significantly higher (p = 0.024 and p = 0.039 respectively) and the number of related donor kidney transplantation was significantly lower (p = 0.018) in the EAR group. EAR-patients showed lower CD4+CD28null T-cell numbers (p<0.01) and the same trend was observed for CD8+CD28null T-cell numbers (p = 0.08). No differences regarding the other ageing parameters were found. A multivariate Cox regression analysis showed that higher CD4+CD28null T-cell numbers was associated with a lower risk for EAR (HR: 0.65, p = 0.028). In vitro, a significant lower percentage of alloreactive T cells was observed within CD28null T cells (p<0.001). Conclusion Immunological ageing-related expansion of highly differentiated CD28null T cells is associated with a lower risk for EAR.


Blood Purification | 2004

Vitamin E-Coated Dialyzer Membranes Downregulate Expression of Monocyte Adhesion and Co-Stimulatory Molecules

Michiel G.H. Betjes; Franciska M.E. Hoekstra; Mariska Klepper; Saskia M. Postma; L. M. B. Vaessen

Background: In patients on chronic hemodialysis leukocyte activation has been related to the impaired function of the immune system. In this study we investigated if the vitamin E-coated dialyzer membrane could reduce monocyte activation thereby improving cellular immunity. Methods: This hypothesis was tested in a prospective crossover trial in which 14 stable hemodialysis patients were switched from the baseline hemophane dialyzer to a vitamin E-coated and thereafter a polysulphone dialyzer membrane or vice versa. Results: Monocyte MHC class I, CD54 and ICAM-1 expression was significantly downregulated when a vitamin E-coated or polysulphone dialyzer was used. The use of a vitamin E membrane specifically decreased monocyte CD40 and CD86 expression. Lectin induced T cell proliferation increased with the use of the vitamin E-coated membrane as compared to polysulphone and hemophane dialyzers. Conclusion: Vitamin E-coated dialyzers induced a less-activated phenotype of monocytes and may improve cellular immunity.

Collaboration


Dive into the Mariska Klepper's collaboration.

Top Co-Authors

Avatar

Carla C. Baan

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Willem Weimar

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Nicolle H.R. Litjens

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Michiel G.H. Betjes

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Anne P. Bouvy

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Marcia M.L. Kho

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

A.M.A. Peeters

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Dennis A. Hesselink

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Burç Dedeoglu

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Jurjen H.L. Velthuis

Erasmus University Rotterdam

View shared research outputs
Researchain Logo
Decentralizing Knowledge